肿瘤CTC和ctDNA介绍

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy,

Catherine Alix-Panabières,Cancer Discov;6(5); 479–91. ©2016 AACR Published OnlineFirst March 11, 2016; DOI: 10.1158/2159-8290.CD-15-1483.

原发肿瘤（乳房、结肠、肺、前列腺癌）在形成生长早期，会释放细胞进入血液循环。通过各种技术可以富集检测这些循环肿瘤细胞的物理和生物性质。

循环肿瘤细胞，Circulating Tumor cell，简称CTC。CTC释放点：原发肿瘤和转移肿瘤。

CTC死亡后还会释放出循环肿瘤DNA，Circulating Tumor DNA，简称ctDNA。

CTCs和ctDNA的分析是液体活检诊断的基石。

CTC和ctDNA的临床应用

肿瘤检测：CTCs和ctDNA应用肿瘤的早期检测很受关注，面临的挑战是目前分析的特定性和敏感度。

预后评估：多种肿瘤已经实现预后评估，尤其是乳癌。

指导系统治疗：

病人亚群分类（stratification）。

CTC研究进展

CTC研究是很活跃的领域，截止2015年12月发表在PubMed的文献有17000篇。随着循环游离肿瘤DNA分析的发展，zui近才开始使用“液体活检”这个条目。分子水平的灵敏分析方便研究者从血浆中筛选特定肿瘤突变的ctDNA，因此ctDNA和CTC成为富有竞争力的生物标志物。不过建议把ctDNA和CTC作为两种互补的信息资源，根据应用区分。文章简单讨论生物和检测技术，重点是ctDNA和CTC的肿瘤临床应用。

血浆游离循环肿瘤DNA（ctDNA）保存管

——Streck Cell-Free DNA BCT® 血浆游离DNA采血/保存管内含特殊保护剂，可以保护血浆循环游离DNA（包括游离循环肿瘤DNA），常温下可以保存CTC达14天。

英文名称：Streck Cell-Free DNA BCT® BLOOD COLLECTION TUBE

中文名称：Streck BCT® 血浆游离DNA采血/保存管

货号：218962,230253

Streck 血浆游离DNA采血管是一种直接提取的全血收集管，用于收集、运输和储存血液样本。Streck 血浆游离DNA采血管内含防腐剂，它能稳定有核血细胞，防止细胞基因组DNA的释放，保护血浆游离循环DNA和循环肿瘤细胞（CTC）。

230253是Streck Cell-Free DNA BCT® 10mL采血管218962的升级版，是Streck公司新推将玻璃和塑料的*性能融合在一起的Fusion2^TM混合塑料管。

Streck Cell-Free DNA BCT® 血浆游离DNA采血/保存管应用

NIPT无创产前检测：孕妇外周血的胎儿游离DNA保存

肿瘤液体活检：循环肿瘤细胞（CTCs）和ctDNA（循环肿瘤DNA）保存

其他：血浆基因组DNA和游离DNA保存

Streck Cell-Free DNA BCT® 血浆游离DNA采血/保存管基因保存性能

游离DNA、细胞内基因组DNA和循环肿瘤细胞样本保存/稳定性

血浆游离循环肿瘤DNA（ctDNA）保存管

Streck 218962（现货）,230253 Cell-Free DNA BCT采血管及更多液体活检产品欢迎您咨询华雅再生医学旗舰公司：红荣微再（上海）生物工程技术有限公司  ：1500 1904 520。红荣微再-客服: 2395557778  经销商专员。红荣微再以“传递科学价值，服务科学研究”为宗旨，主营干细胞、医疗、细胞治疗、器官再生四大板块的产品。

血浆游离循环肿瘤DNA（ctDNA）保存管

Streck BCT采血管的Circulating Tumor DNA (ctDNA)保存文献

Development and clinical utility of a blood-based test service for the rapid identification of actionable mutations in non-small cell lung carcinoma

Mellert H., Foreman T., Jackson L, Maar D., Thurston S., Koch K. et al.

The Journal of Molecular Diagnostics, May 2017.

Application of circulating tumor DNA in prospective clinical oncology trials –standardization of preanalytical conditions

van Dessel L.F., Beije N., Helmijr J.C., Vitale S.R., Kraan J., Look M.P., et al.

Molecular Oncology, 2017.

Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: comparison to ctDNA and tissue in metastatic colorectal cancer

Kidess-Sigal E., Liu H.E., Triboulet M.M., Che J, Ramani V.C., Visser B.C., et al.

Oncotarget November, 2016.

Performance of Streck cfDNA blood collection tubes for liquid biopsy testing

Diaz I.M., Nocon A., Mehnert D.H., Fredebohm J., Diehl F.,Holtrup F.

PLoS One, 2016

Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer

Sacher A.G., Paweletz C., Dahlberg S., Alden R., O’Connell A., Feeney N., et al.

Journal of the American Medical Association Oncology, 2016.

Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next generation sequencing of cell-free circulating tumor DNA

Thompson J.C., Yee S.S., Troxel A.B., Savitch S.L., Fan R., Balli D., et al.

Clinical Cancer Research, 2016.

Optimized pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC)

Sherwood J.L., Corcoran C., Brown H., Sharpe A.D., Musilova M.,Kohlman A.

PLoS One, 2016.

ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients

Chu D., Paoletti C., Gersch C., VanDenBerg D.A., Zabransky D.J., Cochran R.L., et al.

Clinical Cancer Research, 2016.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

Schiavon G., Hrebien S., Garcia-Murillas I., Cutts R.J., Pearson A., Tarazona N., et al.

Science Translational Medicine, 2015.

Analytical and clinical validation of a digital Measurement of circulating cell-free DNA in sequencing panel for quantitative, highly accurate relation to 18F-fluorocholine PET/CT imaging in evaluation of cell-free circulating tumor DNA chemotherapy-treated advanced prostate cancer

Lanman R.B., Mortimer S.A., Zill O.A., Sebisanovic D., Kwee S., Song M.A., Cheng I., Loo L., Tiirikainen M.,Lopez R., Blau S., et al. Clinical & Translational Science, 2012.

PLoS One, 2015.

Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas

Zill O.A., Greene C., Sebisanovic D., Siew L., Leng J., Vu M., et al. Cancer Discovery, 2015.

Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA

Toro P.V., Erlanger B., Beaver J.A., Cochran R.L., VanDenBerg D.A., Yakim E., et al.

Clinical Biochemistry, 2015.

Detection of clonal and subclonal copy-number variants in cell-free DNA from patients with breast cancer using a massively multiplexed PCR methodology

Kirkizlar E., Zimmermann B., Constantin T., Swernerton R., Hoang B., Wayham N., et al.

Translational Oncology, 2015.

Efficient detection of BRAF mutation in plasma of patients after long-term storage of blood in cell‑free DNA blood collection tubes

Denis M.G., Knol A.C., Theoleyre S., Vallee A., Dreno B. Clinical Chemistry, 2015.

Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study

Vandenberghe P., Wlodarska I., Tousseyn T., Dehaspe L., Dierickx D., Verheecke M., et al.

The Lancet, 2015.

Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform

Kidess E., Heirich K., Wiggin M., Vysotskaia V., Visser B.C., Marziali A., et al.

Oncotarget, 2014.

血浆游离循环肿瘤DNA（ctDNA）保存管

——Streck Cell-Free DNA BCT® 血浆游离DNA采血/保存管

订购信息

血浆游离循环肿瘤DNA（ctDNA）保存管

Streck 218962（现货）,230253 Cell-Free DNA BCT采血管及更多液体活检产品欢迎您咨询华雅再生医学旗舰公司：红荣微再（上海）生物工程技术有限公司  ：1500 1904 520。红荣微再-客服: 2395557778  经销商专员。红荣微再以“传递科学价值，服务科学研究”为宗旨，主营干细胞、医疗、细胞治疗、器官再生四大板块的产品。